Studies on CYP3A Activity During the Menstrual Cycle As Measured by Urinary 6β-hydroxycortisol/cortisol

Overview

Journal Pharmacol Res Perspect

Date 2021 Oct 19

PMID 34664787

Citations 2

Authors

Helena Bergstrom

Anna Lindahl

Anna Warnqvist

Ulf Diczfalusy

Lena Ekstrom

Linda Bjorkhem-Bergman

Affiliations

Soon will be listed here.

Abstract

The 6β-OH-cortisol/cortisol ratio (6β-OHC/C) in urine is an endogenous marker of drug-metabolizing enzyme cytochrome P450 3A (CYP3A). The primary aim of this single center, prospective, non-interventional cohort study, was to investigate the variability of 6β-OHC/C during the menstrual cycle. In addition, possible associations between the CYP3A activity and sex hormones, gut microbiota metabolite trimethylamine-N-Oxide (TMAO) and microRNA-27b, respectively, were investigated. Serum and urinary samples from healthy, regularly menstruating women followed for two menstrual cycles were analyzed. Twenty-six complete menstrual cycles including follicular, ovulatory, and luteal phase were defined based on hormone analyses in serum. 6β-OHC/C were analyzed in urine and sex hormones, TMAO and miRNA-27b were analyzed in serum at the same time points. 6β-OHC/C did not vary between the follicular, ovulatory, or luteal phases. There was a difference in the relative miRNA-27b expression between the follicular and ovulatory phase (p = .03). A significant association was found between 6β-OHC/C and progesterone during the follicular (p = .005) and ovulatory (p = .01) phases (n = 26 for each phase). In addition, a significant association was found between the ratio and TMAO during the ovulatory (p = .02) and luteal (p = .002) phases. 6β-OHC/C and gut microbiota TMAO were significantly associated (p = .003) when evaluating all values, for all phases (n = 78). Interestingly, the finding of an association between 6β-OHC/C in urine and levels of TMAO in serum suggest that gut microbiota may affect CYP3A activity.

Citing Articles

Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice.

Kumondai M, Ogawa R, Hayashi N, Ishida Y, Oshikiri H, Sato Y Pharmacol Res Perspect. 2024; 12(4):e1241.

PMID: 38992911 PMC: 11239757. DOI: 10.1002/prp2.1241.

Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol.

Bergstrom H, Lindahl A, Warnqvist A, Diczfalusy U, Ekstrom L, Bjorkhem-Bergman L Pharmacol Res Perspect. 2021; 9(6):e00884.

PMID: 34664787 PMC: 8525181. DOI: 10.1002/prp2.884.

References

Jarmusch A, Vrbanac A, Momper J, Ma J, Alhaja M, Liyanage M . Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. Clin Transl Sci. 2020; 13(5):972-984. PMC: 7485946. DOI: 10.1111/cts.12785. View

Kirkwood C, Moore A, Hayes P, DeVane C, Pelonero A . Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther. 1991; 50(4):404-9. DOI: 10.1038/clpt.1991.157. View

Perez-Cremades D, Mompeon A, Vidal-Gomez X, Hermenegildo C, Novella S . miRNA as a New Regulatory Mechanism of Estrogen Vascular Action. Int J Mol Sci. 2018; 19(2). PMC: 5855695. DOI: 10.3390/ijms19020473. View

Lutz U, Bittner N, Ufer M, Lutz W . Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 878(1):97-101. DOI: 10.1016/j.jchromb.2009.11.023. View

Waxman D, Holloway M . Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol. 2009; 76(2):215-28. PMC: 2713118. DOI: 10.1124/mol.109.056705. View

Ducharme J, Polic V, Auclair K . A Covalently Attached Progesterone Molecule Outcompetes the Binding of Free Progesterone at an Allosteric Site of Cytochrome P450 3A4. Bioconjug Chem. 2019; 30(6):1629-1635. DOI: 10.1021/acs.bioconjchem.9b00248. View

Chen M, Ma L, Drusano G, Bertino Jr J, Nafziger A . Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther. 2006; 80(5):531-8. DOI: 10.1016/j.clpt.2006.08.014. View

Kharasch E, Mautz D, Senn T, Lentz G, Cox K . Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol. 1999; 39(3):275-80. View

Kabekkodu S, Shukla V, Varghese V, D Souza J, Chakrabarty S, Satyamoorthy K . Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc. 2018; 93(4):1955-1986. DOI: 10.1111/brv.12428. View

10.

Jourova L, Vavreckova M, Zemanova N, Anzenbacher P, Langova K, Hermanova P . Gut Microbiome Alters the Activity of Liver Cytochromes P450 in Mice With Sex-Dependent Differences. Front Pharmacol. 2020; 11:01303. PMC: 7566554. DOI: 10.3389/fphar.2020.01303. View

11.

Morgan E, Skubic C, Lee C, Blagotinsek Cokan K, Rozman D . Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease. Drug Metab Rev. 2020; 52(4):455-471. PMC: 7709541. DOI: 10.1080/03602532.2020.1817061. View

12.

Bergstrom H, Lindahl A, Warnqvist A, Diczfalusy U, Ekstrom L, Bjorkhem-Bergman L . Studies on CYP3A activity during the menstrual cycle as measured by urinary 6β-hydroxycortisol/cortisol. Pharmacol Res Perspect. 2021; 9(6):e00884. PMC: 8525181. DOI: 10.1002/prp2.884. View

13.

Bergstrom H, Ekstrom L, Warnqvist A, Bergman P, Bjorkhem-Bergman L . Variations in biomarkers of dyslipidemia and dysbiosis during the menstrual cycle: a pilot study in healthy volunteers. BMC Womens Health. 2021; 21(1):166. PMC: 8058971. DOI: 10.1186/s12905-021-01306-4. View

14.

Dempsey J, Cui J . Microbiome is a functional modifier of P450 drug metabolism. Curr Pharmacol Rep. 2020; 5(6):481-490. PMC: 7731899. DOI: 10.1007/s40495-019-00200-w. View

15.

Zhu B, Liu Z, Chen G, Chen X, Ou-Yang D, Wang L . The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol. 2003; 55(3):264-9. PMC: 1884221. DOI: 10.1046/j.1365-2125.2003.01728.x. View

16.

Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

17.

Lee Y, Chae W, Yoon S, Chung J, Cho J . Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A. Transl Clin Pharmacol. 2020; 28(2):73-82. PMC: 7327190. DOI: 10.12793/tcp.2020.28.e10. View

18.

Guttman Y, Nudel A, Kerem Z . Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related. Front Genet. 2019; 10:224. PMC: 6433705. DOI: 10.3389/fgene.2019.00224. View

19.

Bjorkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E, Andersson T . Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos. 2013; 41(8):1488-93. DOI: 10.1124/dmd.113.052316. View

20.

Wolbold R, Klein K, Burk O, Nussler A, Neuhaus P, Eichelbaum M . Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003; 38(4):978-88. DOI: 10.1053/jhep.2003.50393. View